Analysis of regulatory documents to strengthen the HPV vaccination system and early detection of cervical cancer in the Republic of Tajikistan

Objective: o analyze the regulatory framework of the Republic of Tajikistan in the field of oncology in order to optimize the national model for early detection of cervical cancer.

Material and methods: A retrospective analysis was performed on 20 regulatory acts, national strategies, ministerial decrees, and international health system reviews from 2016 to 2025, using systemic and comparative descriptive methods.

Results: The study outlines the evolution of the national regulatory framework, from isolated pilot projects to a systemic approach embodied in the National Program for the Prevention and Control of Oncological Diseases for 2025–2029 (Decree No. 327). Another important step was Resolution No. 408, which regulated the launch of a universal HPV vaccination campaign for girls aged 10–14 in primary health care (PHC) facilities. At the clinical level, Decree No. 841 standardized cervical cytology using the Bethesda system (LSIL/HSIL). The authors substantiate the need for legislative consolidation of national digital monitoring algorithms through the Health Management Information System, which would improve the accessibility of preventive and diagnostic services for women facing financial and geographical barriers.

Conclusions: Tajikistan’s regulatory framework for the control of cervical cancer has been aligned with international WHO standards. Future efforts should focus on legally defining automated cross-level monitoring between primary care and specialized cancer centers.

1. Population health and activities of healthcare institutions in 2025. Dushanbe: RCSMI. 2026;362. (In Russ.).

2. Agency on Statistics under the President of the Republic of Tajikistan, Ministry of Health and Social Protection of the Population of the Republic of Tajikistan, ICF. Tajikistan Demographic and Health Survey 2023. Dushanbe: Agency on Statistics under the President of the Republic of Tajikistan, ICF. 2025;412. (In Russ.).

3. Abdullozoda J.A., Muhsinzoda G.M., Ashrafyan L.A. et al. First results of mass immunization of girls against human papillomavirus in Tajikistan. Epidemiology and Vaccinal Prevention. Moscow. 2026;25(4): 65-72. https://doi.org/10.31631/2073-3046-2027-25-4-00-00. (In Russ.).

4. Muhsinzoda N.A., Muhsinzoda G.M., Sattorov S.S., Tursunzoda R.A. Prevalence of human papillomavirus infection and cervical pathology in women with different HIV status. Problems in Oncology. Saint Petersburg. 2025;71(6):1271-2282. https://doi.org/10.37469/0507-3758-2025-71-6-OF-2282. (In Russ.).

5. Khodjamurodov G., Sodiqova D., Akkazieva B., Rechel B. Tajikistan: health system review. Health Systems in Transition. 2016;18(1):1-114.

6. Sodiqova D., Muhsinzoda H., Dorghabekova N., et al. Tajikistan: Health system review 2025. Health Systems in Transition. 2025;27(1):1-188.

7. Resolution of the Government of the Republic of Tajikistan No. 327 dated 29.05.2025 “On the Program for the Prevention and Control of Cancer Diseases in the Republic of Tajikistan for 2025–2029”. Dushanbe; 2025. (In Russ.).

8. Resolution of the Government of the Republic of Tajikistan No. 479 dated 20.08.2024 “Strategy for the Prevention, Control of Noncommunicable Diseases and Injuries in the Republic of Tajikistan for the Period up to 2040”. Dushanbe; 2024. (In Russ.).

9. Resolution of the Government of the Republic of Tajikistan No. 408 dated 24.07.2025 “On Conducting a Mass Immunization Campaign against Human Papillomavirus in the Republic of Tajikistan”. Dushanbe; 2025. (In Russ.).

10. Order of the Ministry of Health and Social Protection of the Population of the Republic of Tajikistan No. 926 dated 23.11.2020 “Action Plan for Prevention, Early Diagnosis, Treatment and Palliative Care for Patients with Cervical Cancer for the Period 2021–2030”. Dushanbe; 2020. (In Russ.).

11. Order of the Ministry of Health and Social Protection of the Population of the Republic of Tajikistan No. 917 dated 26.12.2022 “Clinical Guideline on “Prevention and Screening of Cervical Cancer””. Dushanbe; 2022. 58 p. (In Russ.).

12. Dzhuraev A.S., Vasikhov N.A., Muhsinzoda N.A. Clinical guideline “cytological examination of material (during gynecological examination, screening)”. Order of the Ministry of Health and Social Protection of the Population No. 841 dated 24.11.2024. Dushanbe; 2024. (In Russ.).

13. Muhsinzoda N.A. HPV DNA screening in women living with HIV in Tajikistan: an educational and methodological manual. Dushanbe: Irfon. 2025;80. (In Russ.).

14. Murodzoda A.I., Muhsinzoda N.A., Ulrikh E.A. Cervical cancer: clinical guideline. Dushanbe: Kontrast. 2025;36. (In Russ.).

15. Sukhikh G.T., Prilepskaya V.N. Prevention of cervical cancer: a guide for physicians. 3rd ed., revised and enlarged. Moscow: MEDpress-inform. 2012;192. (In Russ.).

16. Broutet N., Sauvaget M., Stanley M., et al. World Health Organization global strategy to accelerate the elimination of cervical cancer as a public health problem. International Journal of Gynecology & Obstetrics. 2021;152(1):11-14. https://doi.org/10.1002/ijgo.13812

17. Ouh Y.-T., Kim H.Y., Yi K.W., Lee N.-W., Kim H.-J., Min K.-J. Enhancing Cervical Cancer Screening: Review of p16/Ki-67 Dual Staining as a Promising Triage Strategy. Diagnostics. 2024;14(4):451. https://doi.org/10.3390/diagnostics14040451

18. Beglyarzade S.A., Mukhametova R.R., Zhao B. Prospects for screening and therapy of cervical cancer. Creative Surgery and Oncology. 2024;14(1):60-68. (In Russ.).

19. Russian Society of Obstetricians and Gynecologists. Cervical intraepithelial neoplasia, erosion and ectropion of the cervix: clinical guidelines. Moscow. 2026;60. (In Russ.).

20. Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva: WHO; 2022. URL: https://www.who.int (accessed: 10.03.2025). (In Russ.).

21. World Health Organization. Human papillomavirus vaccines: WHO position paper. Weekly Epidemiological Record. 2022;97(50):645-672. World Health Organization. Comprehensive cervical cancer control: a guide to essential practice. 2nd ed. Geneva: WHO; 2014.

22. Muhsinzoda N.A., Muhsinzoda G.M., Saidzoda F.B., Tursunov R.A. Preparing the health system for routine vaccination against human papillomavirus. Eurasian Scientific and Medical Journal “Sino”. 2024;5(1):5-20. https://doi.org/10.54538/2707-5265-2024-5-1-5-20. (In Russ.).

23. Abdullozoda J.A., Saidzoda F.B., Murodzoda A.I. et al. Effectiveness and clinical safety of vaccination against human papillomavirus. Healthcare of Tajikistan. 2025;366(3):11-19. https://doi.org/10.52888/0514-2515-2025-366-3-11-19. (In Russ.).